References
- Quint JK, Arnetorp S, Kocks JWH, et al. Short-acting beta-2-agonist exposure and severe asthma exacerbations: SABINA findings from Europe and North America. J Allergy Clin Immunol Pract. 2022;10(9):2297–2309. doi:10.1016/j.jaip.2022.02.047
- Heatley H, Tran TN, Bourdin A, et al. Observational UK cohort study to describe intermittent oral corticosteroid prescribing patterns and their association with adverse outcomes in asthma. Thorax. 2022. doi:10.1136/thorax-2022-219642
- Global Initiative for Asthma. Global strategy for asthma management and prevention, 2023. Updated May 2023. Available from: https://ginasthma.org. Accessed May 18, 2023.
- National Heart, Lung, and Blood Institute (NHLBI). Guidelines for the Diagnosis and Management of Asthma (EPR3 & Focused Update). Available from: https://www.nhlbi.nih.gov/health-topics/guidelines-for-diagnosis-management-of-asthma. Accessed May 18, 2023.
- Papi A, Chipps BE, Beasley R, et al. Albuterol-budesonide fixed-dose combination rescue inhaler for asthma. N Engl J Med. 2022;386(22):2071–2083. doi:10.1056/NEJMoa2203163
- Israel E, Cardet JC, Carroll JK, et al. Reliever-triggered inhaled glucocorticoid in black and latinx adults with asthma. N Engl J Med. 2022;386(16):1505–1518. doi:10.1056/NEJMoa2118813
- Daley-Yates PT. Inhaled corticosteroids: potency, dose equivalence and therapeutic index. Br J Clin Pharmacol. 2015;80(3):372–380. doi:10.1111/bcp.12637